Shih-Cheng Yang
Overview
Explore the profile of Shih-Cheng Yang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
259
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Yeh W, Yang S, Liang C, Li Y, Tai W, Lee C, et al.
Medicina (Kaunas)
. 2020 Jan;
56(1).
PMID: 31905956
: Non-selective β-blockers (NSBB) could prevent decompensation and hepatocellular carcinoma (HCC) in cirrhotic patients with clinically significant portal hypertension (CSPH), but remained uncertain for compensated cirrhotic patients without major complications....
12.
Yang S, Wu C, Tai W, Liang C, Li Y, Yeh W, et al.
J Gastroenterol Hepatol
. 2020 Jan;
35(10):1704-1711.
PMID: 31900958
Background And Aims: Colonoscopic polypectomy in end-stage renal disease (ESRD) patients are at risks of post-polypectomy bleeding and perforation, but evidences are limited. This study aimed to determine the incident...
13.
Wu C, Yang S, Liang C, Li Y, Yeh W, Tai W, et al.
J Gastroenterol Hepatol
. 2019 Nov;
35(5):777-787.
PMID: 31674688
Background And Aim: Antibiotic prophylaxis should be instituted for cirrhotic patients with upper gastrointestinal bleeding (UGIB), but the benefit on compensated patients remains undetermined. We aimed to compare the clinical...
14.
Liang C, Yang S, Wu C, Li Y, Yeh W, Tai W, et al.
J Clin Med
. 2019 Oct;
8(10).
PMID: 31635253
The purpose of this population-based case-control study was to clarify the impact of cumulative dosage of nonsteroidal anti-inflammatory drugs (NSAIDs) on recurrent peptic ulcers among chronic users after eradication. We...
15.
Tai W, Liang C, Bi K, Kuo C, Lu L, Wu C, et al.
Infect Drug Resist
. 2019 Oct;
12:2923-2931.
PMID: 31571945
Purpose: Steadily maintaining high intra-gastric PH is the major factor for successful eradication. It is important to search for a stronger PPI. Dexlansoprazole MR is a dual delayed release formulation...
16.
Yao C, Kuo C, Hsu C, Yang S, Wu C, Tai W, et al.
Infect Drug Resist
. 2019 Jun;
12:1425-1431.
PMID: 31239721
To assess the difference of the first-line therapy for in patients with or without type 2 diabetes (DM) and to investigate the clinical factors influencing treatment outcomes. In total, 719...
17.
Chiang H, Wu D, Hsu P, Kuo C, Tai W, Yang S, et al.
Drug Des Devel Ther
. 2019 May;
13:1347-1356.
PMID: 31118571
Research comparing the clinical efficacy of dexlansoprazole and esomeprazole has been limited. This study aims to compare the clinical efficacy of single doses of dexlansoprazole (modified-release 60 mg) and esomeprazole...
18.
Tai W, Liang C, Kuo C, Huang P, Wu C, Yang S, et al.
J Antimicrob Chemother
. 2019 Feb;
74(6):1718-1724.
PMID: 30768161
Background: The first-line eradication rate of standard triple therapy for Helicobacter pylori infection has declined to <80%, and alternative therapies with >90% success rates are needed. Inconsistent eradication rates were...
19.
Nguang S, Wu C, Liang C, Tai W, Yang S, Ku M, et al.
Int J Environ Res Public Health
. 2018 Nov;
15(12).
PMID: 30486324
Hepatitis B virus vaccination and antiviral therapies reduce the risk of hepatocellular carcinoma (HCC). However, the lifetime healthcare expenditure involved in caring for HCC patients remains unclear. We examined the...
20.
Huang H, Wang H, Yang S, Tai W, Liang C, Wu K, et al.
Infect Drug Resist
. 2018 Nov;
11:2073-2080.
PMID: 30464550
Purpose: To assess the efficacy of amoxicillin, tetracycline, high-dose metronidazole, and a proton-pump inhibitor for third-line eradication. Methods: We enrolled 70 consecutive patients who had registered, failed to respond to...